PDSB
PDS Biotechnology Corp
Key Financials
Net Income
$-34495505
↓ 356.1%
Total Assets
$30.5M
↓ 32.8%
EPS (Diluted)
$-0.74
↑ 28.2%
Total Liabilities
$21.2M
↓ 19.4%
Operating Income
$-31543959
↑ 13.2%
Cash & Equivalents
$26.7M
↓ 35.9%
Operating Cash Flow
$-27752012.00
↑ 20.8%
Long-term Debt
$5.5M
N/A
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 8/14/2026 | View on SEC |
| 10-Q | 8/13/2026 | View on SEC |
| 8-K | 8/13/2026 | View on SEC |
| 8-K | 8/11/2026 | View on SEC |
| 8-K | 7/31/2026 | View on SEC |
| EFFECT | 7/21/2026 | View on SEC |
| 424B4 | 7/21/2026 | View on SEC |
| S-3 | 7/10/2026 | View on SEC |
| ARS | 6/26/2026 | View on SEC |
| DEFA14A | 6/26/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | PDSB |
| Company Name | PDS Biotechnology Corp |
| CIK | 1472091 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 800-208-3343 |